Published in:
Open Access
01-08-2019 | Metastasis | Review Article
The RANK–RANKL axis: an opportunity for drug repurposing in cancer?
Authors:
S. Peters, P. Clézardin, I. Márquez-Rodas, D. Niepel, C. Gedye
Published in:
Clinical and Translational Oncology
|
Issue 8/2019
Login to get access
Abstract
Drug repurposing offers advantages over traditional drug development in terms of cost, speed and improved patient outcomes. The receptor activator of nuclear factor kappa B (RANK) ligand (RANKL) inhibitor denosumab is approved for the prevention of skeletal-related events in patients with advanced malignancies involving bone, including solid tumours and multiple myeloma. Following improved understanding of the role of RANK/RANKL in cancer biology, denosumab has already been repurposed as a treatment for giant cell tumour of bone. Here, we review the role of RANK/RANKL in tumourigenesis, including effects on tumour initiation, progression and metastasis and consider the impact of RANK/RANKL on tumour immunology and immune evasion. Finally, we look briefly at ongoing trials and future opportunities for therapeutic synergy when combining denosumab with anti-cancer agents such as immune checkpoint inhibitors.